Fundamental advancement of knowledge of Plasmodium vivax biology, drug susceptibility and transmission

间日疟原虫生物学、药物敏感性和传播知识的根本进步

• 批准号: nhmrc : 1052760
• 负责人: Dr Stephan Karl
• 金额: $ 21.08万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/fundamental-advancement-knowledge-susceptibility-transmission/112296
• 关键词: Fundamental; advancement; knowledge; Plasmodium; vivax

Plasmodium vivax is the most widespread malaria parasite causing over 80 million cases per year. Yet, current means to counter this parasite are grossly inadequate. Vast knowledge gaps exist due to unavailability of continuous cultures, high throughput drug assays and the poor understanding of transmission. This inhibits the development of new treatments for P. vivax. This project will fundamentally advance knowledge of the biology and epidemiology of this important, but neglected pathogen.

间日疟原虫是分布最广的疟疾寄生虫，每年造成8000万人以上的疟疾病例。然而，目前对抗这种寄生虫的手段严重不足。由于无法获得连续培养、高通量药物分析和对传播的了解不足，存在着巨大的知识差距。这抑制了间日疟原虫新疗法的开发。该项目将从根本上促进对这种重要但被忽视的病原体的生物学和流行病学的了解。